CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.
about
CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-α-Gabpa and stress-induced adaptive responses via NF-κB-cMYCCancer-relevant Splicing Factor CAPERα Engages the Essential Splicing Factor SF3b155 in a Specific Ternary ComplexCAPER, a novel regulator of human breast cancer progression.Coordinated control of senescence by lncRNA and a novel T-box3 co-repressor complex.Overexpression of HCC1/CAPERα may play a role in lung cancer carcinogenesis.Serum autoantibody measurement for the detection of hepatocellular carcinomaThe origins, evolution, and functional potential of alternative splicing in vertebrates.The c-Rel Transcription Factor in Development and Disease.Unbiased proteomic analysis of proteins interacting with the HIV-1 5'LTR sequence: role of the transcription factor Meis.UHM-ULM interactions in the RBM39-U2AF65 splicing-factor complex.Essential role of cooperative NF-κB and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in gliomaTumor-associated antigen CAPERα and microvessel density in hepatocellular carcinoma.Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors.Autoantibodies, autoimmune disease, and the birth of immune diagnostics.Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC).Antinuclear antibodies defining autoimmunity pathways.Unmasking the U2AF homology motif family: a bona fide protein-protein interaction motif in disguise.Activation of gga-miR-155 by reticuloendotheliosis virus T strain and its contribution to transformation.Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
P2860
Q27311336-FC7DECFF-368C-4EE8-9B5C-F0A2D95F73B5Q27683637-C30A2C23-F215-4086-B67A-1208EFDF7D9FQ33728372-3556478F-BFED-4707-9F0B-167414347503Q33808862-92F5933C-2E4F-4029-8337-80DB899EF3C0Q33946598-E17172C9-3BAF-4387-8429-06061F3C031AQ34004797-AA2B8169-5E49-4892-9562-B8DB7E473CD0Q35223510-50986BC2-8E1F-40BC-A0CB-A765B1C3FE3DQ35556506-8278F85B-455D-4EE7-8E18-67CD80D5F82DQ36422209-253ED534-FBE4-4DC9-AFF4-F815B28E8B16Q36770424-6C6088DA-6402-4878-9AA0-64A684C39549Q36877702-90F538B0-353D-4532-8FF4-A84C61600CBBQ37086180-DD4BDEF8-E43D-4348-859A-E9847DC82159Q37724875-D9D82C4D-D714-41F1-B81B-02435629B607Q38060047-125B12D0-80F1-4876-B3E5-F4843AB24892Q38107971-32284648-23BB-4028-A9C7-861BAE997066Q38643832-02490B35-8909-4EE9-9C67-9C040E6CA9CDQ39010502-6D2FE8BA-5296-432B-A908-691BB1BB7E3FQ40361877-43B03CAA-1FF6-47C9-B68F-78390F9B580EQ47664450-12C89FEF-BD68-491C-BA1B-7304E8E4C5E8
P2860
CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
CAPERalpha is a novel Rel-TAD- ...... l/NF-kappaB oncoprotein v-Rel.
@en
type
label
CAPERalpha is a novel Rel-TAD- ...... l/NF-kappaB oncoprotein v-Rel.
@en
prefLabel
CAPERalpha is a novel Rel-TAD- ...... l/NF-kappaB oncoprotein v-Rel.
@en
P2093
P2860
P356
P1433
P1476
CAPERalpha is a novel Rel-TAD- ...... l/NF-kappaB oncoprotein v-Rel.
@en
P2093
Céline Gélinas
Gaofeng Fan
P2860
P304
10792-10802
P356
10.1128/JVI.00903-08
P407
P577
2008-08-27T00:00:00Z